Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML

NCT00780598 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
AML

Interventions

DRUG: Tosedostat

Sponsor

Chroma Therapeutics

Collaborators

[object Object]